Appendix 4C, “December 2018 Quarterly Update” was lodged with the Australian Securities Exchange on 31st January.
View the Appendix 4C.
Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway
September 9, 2025
Highlights Dr Nina Webster appointed as IBX Non-Executive Director, bringing significant clinical development expertise and corporate experienceto the IBX Board ahead of HER2 Breast cancer